Free Trial

Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis

-1.18 (-2.87%)
(As of 05/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
578,640 shs
Average Volume
750,026 shs
Market Capitalization
$3.32 billion
P/E Ratio
Dividend Yield
Price Target

Ultragenyx Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.92 Rating Score
120.2% Upside
$87.85 Price Target
Short Interest
5.59% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.53mentions of Ultragenyx Pharmaceutical in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$1.65 M Sold Last Quarter
Proj. Earnings Growth
From ($6.49) to ($4.92) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.28 out of 5 stars

Medical Sector

110th out of 915 stocks

Pharmaceutical Preparations Industry

39th out of 399 stocks

RARE stock logo

About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

RARE Stock Price History

RARE Stock News Headlines

Ultragenyx: Q1 Earnings Snapshot
See More Headlines
Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
12 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$434.25 million
Book Value
$1.69 per share


Free Float
Market Cap
$3.32 billion

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

RARE Stock Analysis - Frequently Asked Questions

Should I buy or sell Ultragenyx Pharmaceutical stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RARE shares.
View RARE analyst ratings
or view top-rated stocks.

What is Ultragenyx Pharmaceutical's stock price target for 2024?

12 Wall Street research analysts have issued twelve-month target prices for Ultragenyx Pharmaceutical's shares. Their RARE share price targets range from $47.00 to $133.00. On average, they predict the company's share price to reach $87.85 in the next twelve months. This suggests a possible upside of 120.2% from the stock's current price.
View analysts price targets for RARE
or view top-rated stocks among Wall Street analysts.

How have RARE shares performed in 2024?

Ultragenyx Pharmaceutical's stock was trading at $47.82 at the beginning of 2024. Since then, RARE stock has decreased by 16.6% and is now trading at $39.90.
View the best growth stocks for 2024 here

When is Ultragenyx Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our RARE earnings forecast

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced its quarterly earnings data on Thursday, May, 2nd. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing analysts' consensus estimates of ($1.72) by $0.31. The biopharmaceutical company earned $108.83 million during the quarter, compared to analyst estimates of $116.03 million. Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative trailing twelve-month return on equity of 425.63%. The business's revenue was up 8.3% compared to the same quarter last year. During the same period last year, the company posted ($2.33) earnings per share.

What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings?

Ultragenyx Pharmaceutical issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $500.0 million-$530.0 million, compared to the consensus revenue estimate of $513.0 million.

What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?

41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Emil D. Kakkis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.47%), Price T Rowe Associates Inc. MD (4.29%), Clearbridge Investments LLC (2.89%), Avoro Capital Advisors LLC (1.00%), First Light Asset Management LLC (0.95%) and Jacobs Levy Equity Management Inc. (0.83%). Insiders that own company stock include Camille L Bedrosian, Corazon (Corsee) D Sanders, Dennis Karl Huang, Emil D Kakkis, Eric Crombez, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Theodore Alan Huizenga and Thomas Richard Kassberg.
View institutional ownership trends

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RARE) was last updated on 5/24/2024 by Staff

From Our Partners